nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—MTHFR—polycystic ovary syndrome	0.529	1	CbGaD
Methotrexate—Abdominal distress—Metformin—polycystic ovary syndrome	0.0154	0.159	CcSEcCtD
Methotrexate—Anaemia megaloblastic—Metformin—polycystic ovary syndrome	0.00883	0.0911	CcSEcCtD
Methotrexate—Taste metallic—Metformin—polycystic ovary syndrome	0.00654	0.0675	CcSEcCtD
Methotrexate—Reaction gastrointestinal—Metformin—polycystic ovary syndrome	0.00623	0.0643	CcSEcCtD
Methotrexate—Appetite absent—Metformin—polycystic ovary syndrome	0.00418	0.0431	CcSEcCtD
Methotrexate—ABCC11—embryo—polycystic ovary syndrome	0.004	0.024	CbGeAlD
Methotrexate—Azotaemia—Metformin—polycystic ovary syndrome	0.0039	0.0403	CcSEcCtD
Methotrexate—SLC22A8—urine—polycystic ovary syndrome	0.00332	0.0199	CbGeAlD
Methotrexate—Nail disorder—Metformin—polycystic ovary syndrome	0.00321	0.0331	CcSEcCtD
Methotrexate—FOLR1—endometrium—polycystic ovary syndrome	0.00305	0.0183	CbGeAlD
Methotrexate—FOLR1—uterus—polycystic ovary syndrome	0.00281	0.0169	CbGeAlD
Methotrexate—FOLR1—pituitary gland—polycystic ovary syndrome	0.00276	0.0166	CbGeAlD
Methotrexate—Fungal infection—Metformin—polycystic ovary syndrome	0.00269	0.0278	CcSEcCtD
Methotrexate—SLC19A1—adipose tissue—polycystic ovary syndrome	0.00241	0.0145	CbGeAlD
Methotrexate—ATIC—embryo—polycystic ovary syndrome	0.00236	0.0141	CbGeAlD
Methotrexate—SLC46A1—adrenal cortex—polycystic ovary syndrome	0.00231	0.0138	CbGeAlD
Methotrexate—FOLR1—female gonad—polycystic ovary syndrome	0.0023	0.0138	CbGeAlD
Methotrexate—ABCC11—female gonad—polycystic ovary syndrome	0.0022	0.0132	CbGeAlD
Methotrexate—SLC19A1—adrenal gland—polycystic ovary syndrome	0.00216	0.013	CbGeAlD
Methotrexate—FOLR1—endocrine gland—polycystic ovary syndrome	0.00214	0.0128	CbGeAlD
Methotrexate—ABCC11—endocrine gland—polycystic ovary syndrome	0.00205	0.0123	CbGeAlD
Methotrexate—GGH—endometrium—polycystic ovary syndrome	0.00203	0.0122	CbGeAlD
Methotrexate—FPGS—adrenal cortex—polycystic ovary syndrome	0.002	0.012	CbGeAlD
Methotrexate—SLC19A1—endocrine gland—polycystic ovary syndrome	0.00188	0.0112	CbGeAlD
Methotrexate—GGH—uterus—polycystic ovary syndrome	0.00187	0.0112	CbGeAlD
Methotrexate—SLC46A1—pituitary gland—polycystic ovary syndrome	0.00186	0.0112	CbGeAlD
Methotrexate—GGH—pituitary gland—polycystic ovary syndrome	0.00183	0.011	CbGeAlD
Methotrexate—GGH—adipose tissue—polycystic ovary syndrome	0.00183	0.011	CbGeAlD
Methotrexate—SLCO4C1—endometrium—polycystic ovary syndrome	0.0018	0.0108	CbGeAlD
Methotrexate—FPGS—endometrium—polycystic ovary syndrome	0.00178	0.0107	CbGeAlD
Methotrexate—SLC46A1—adrenal gland—polycystic ovary syndrome	0.00167	0.00999	CbGeAlD
Methotrexate—GGH—adrenal gland—polycystic ovary syndrome	0.00164	0.00983	CbGeAlD
Methotrexate—FPGS—pituitary gland—polycystic ovary syndrome	0.00161	0.00967	CbGeAlD
Methotrexate—FPGS—adipose tissue—polycystic ovary syndrome	0.00161	0.00963	CbGeAlD
Methotrexate—ATIC—uterus—polycystic ovary syndrome	0.00159	0.00953	CbGeAlD
Methotrexate—DHFR—embryo—polycystic ovary syndrome	0.00158	0.00949	CbGeAlD
Methotrexate—SLCO1B3—pituitary gland—polycystic ovary syndrome	0.00158	0.00948	CbGeAlD
Methotrexate—ATIC—adipose tissue—polycystic ovary syndrome	0.00155	0.00932	CbGeAlD
Methotrexate—SLC46A1—female gonad—polycystic ovary syndrome	0.00155	0.00932	CbGeAlD
Methotrexate—Lethargy—Metformin—polycystic ovary syndrome	0.00154	0.0159	CcSEcCtD
Methotrexate—GGH—female gonad—polycystic ovary syndrome	0.00153	0.00917	CbGeAlD
Methotrexate—GGH—vagina—polycystic ovary syndrome	0.00152	0.00911	CbGeAlD
Methotrexate—Folic Acid—MTHFR—polycystic ovary syndrome	0.00145	0.5	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—polycystic ovary syndrome	0.00145	0.5	CrCbGaD
Methotrexate—SLC46A1—endocrine gland—polycystic ovary syndrome	0.00144	0.00867	CbGeAlD
Methotrexate—FPGS—adrenal gland—polycystic ovary syndrome	0.00144	0.00864	CbGeAlD
Methotrexate—GGH—endocrine gland—polycystic ovary syndrome	0.00142	0.00852	CbGeAlD
Methotrexate—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00139	0.0144	CcSEcCtD
Methotrexate—ATIC—adrenal gland—polycystic ovary syndrome	0.00139	0.00836	CbGeAlD
Methotrexate—Breast disorder—Metformin—polycystic ovary syndrome	0.00136	0.0141	CcSEcCtD
Methotrexate—SLCO4C1—vagina—polycystic ovary syndrome	0.00135	0.00808	CbGeAlD
Methotrexate—FPGS—female gonad—polycystic ovary syndrome	0.00134	0.00806	CbGeAlD
Methotrexate—FPGS—vagina—polycystic ovary syndrome	0.00134	0.00801	CbGeAlD
Methotrexate—SLCO1B3—vagina—polycystic ovary syndrome	0.00131	0.00785	CbGeAlD
Methotrexate—ATIC—female gonad—polycystic ovary syndrome	0.0013	0.00779	CbGeAlD
Methotrexate—SLCO1C1—pituitary gland—polycystic ovary syndrome	0.0013	0.00778	CbGeAlD
Methotrexate—DHFR—adrenal cortex—polycystic ovary syndrome	0.0013	0.00778	CbGeAlD
Methotrexate—SLCO1C1—adipose tissue—polycystic ovary syndrome	0.00129	0.00775	CbGeAlD
Methotrexate—Pancreatitis—Metformin—polycystic ovary syndrome	0.00128	0.0132	CcSEcCtD
Methotrexate—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00125	0.0129	CcSEcCtD
Methotrexate—FPGS—endocrine gland—polycystic ovary syndrome	0.00125	0.00749	CbGeAlD
Methotrexate—PGD—adrenal cortex—polycystic ovary syndrome	0.00125	0.00748	CbGeAlD
Methotrexate—SLCO1B3—endocrine gland—polycystic ovary syndrome	0.00122	0.00735	CbGeAlD
Methotrexate—Neutropenia—Metformin—polycystic ovary syndrome	0.00122	0.0126	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00121	0.0125	CcSEcCtD
Methotrexate—ATIC—endocrine gland—polycystic ovary syndrome	0.00121	0.00725	CbGeAlD
Methotrexate—TYMS—endometrium—polycystic ovary syndrome	0.00117	0.00701	CbGeAlD
Methotrexate—Drowsiness—Metformin—polycystic ovary syndrome	0.00116	0.012	CcSEcCtD
Methotrexate—Infestation NOS—Metformin—polycystic ovary syndrome	0.00116	0.012	CcSEcCtD
Methotrexate—Infestation—Metformin—polycystic ovary syndrome	0.00116	0.012	CcSEcCtD
Methotrexate—DHFR—endometrium—polycystic ovary syndrome	0.00116	0.00694	CbGeAlD
Methotrexate—MTHFR—adipose tissue—polycystic ovary syndrome	0.00115	0.00693	CbGeAlD
Methotrexate—SLCO3A1—pituitary gland—polycystic ovary syndrome	0.00114	0.00684	CbGeAlD
Methotrexate—SLCO3A1—adipose tissue—polycystic ovary syndrome	0.00114	0.00681	CbGeAlD
Methotrexate—PGD—endometrium—polycystic ovary syndrome	0.00111	0.00667	CbGeAlD
Methotrexate—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.0011	0.0114	CcSEcCtD
Methotrexate—AOX1—adrenal cortex—polycystic ovary syndrome	0.0011	0.00659	CbGeAlD
Methotrexate—ABCC3—adrenal cortex—polycystic ovary syndrome	0.00107	0.00644	CbGeAlD
Methotrexate—ABCC10—adrenal cortex—polycystic ovary syndrome	0.00107	0.00641	CbGeAlD
Methotrexate—DHFR—uterus—polycystic ovary syndrome	0.00107	0.0064	CbGeAlD
Methotrexate—TYMS—adipose tissue—polycystic ovary syndrome	0.00105	0.00632	CbGeAlD
Methotrexate—DHFR—pituitary gland—polycystic ovary syndrome	0.00105	0.00628	CbGeAlD
Methotrexate—Hepatitis—Metformin—polycystic ovary syndrome	0.00104	0.0108	CcSEcCtD
Methotrexate—DHFR—adipose tissue—polycystic ovary syndrome	0.00104	0.00626	CbGeAlD
Methotrexate—SLC16A1—endometrium—polycystic ovary syndrome	0.00104	0.00623	CbGeAlD
Methotrexate—MTHFR—adrenal gland—polycystic ovary syndrome	0.00104	0.00621	CbGeAlD
Methotrexate—PGD—uterus—polycystic ovary syndrome	0.00103	0.00615	CbGeAlD
Methotrexate—SLCO3A1—adrenal gland—polycystic ovary syndrome	0.00102	0.00611	CbGeAlD
Methotrexate—PGD—pituitary gland—polycystic ovary syndrome	0.00101	0.00604	CbGeAlD
Methotrexate—SLCO1C1—endocrine gland—polycystic ovary syndrome	0.001	0.00603	CbGeAlD
Methotrexate—PGD—adipose tissue—polycystic ovary syndrome	0.001	0.00602	CbGeAlD
Methotrexate—AOX1—endometrium—polycystic ovary syndrome	0.00098	0.00588	CbGeAlD
Methotrexate—Eye disorder—Metformin—polycystic ovary syndrome	0.000976	0.0101	CcSEcCtD
Methotrexate—SLC22A11—endocrine gland—polycystic ovary syndrome	0.000976	0.00585	CbGeAlD
Methotrexate—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000969	0.01	CcSEcCtD
Methotrexate—MTHFR—female gonad—polycystic ovary syndrome	0.000966	0.00579	CbGeAlD
Methotrexate—SLC16A1—uterus—polycystic ovary syndrome	0.000957	0.00574	CbGeAlD
Methotrexate—ABCC10—endometrium—polycystic ovary syndrome	0.000954	0.00572	CbGeAlD
Methotrexate—SLC22A7—endocrine gland—polycystic ovary syndrome	0.000952	0.00571	CbGeAlD
Methotrexate—SLCO3A1—female gonad—polycystic ovary syndrome	0.00095	0.0057	CbGeAlD
Methotrexate—Angiopathy—Metformin—polycystic ovary syndrome	0.000948	0.00978	CcSEcCtD
Methotrexate—TYMS—adrenal gland—polycystic ovary syndrome	0.000945	0.00567	CbGeAlD
Methotrexate—SLCO3A1—vagina—polycystic ovary syndrome	0.000944	0.00567	CbGeAlD
Methotrexate—Immune system disorder—Metformin—polycystic ovary syndrome	0.000944	0.00974	CcSEcCtD
Methotrexate—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000941	0.00971	CcSEcCtD
Methotrexate—SLC16A1—pituitary gland—polycystic ovary syndrome	0.00094	0.00564	CbGeAlD
Methotrexate—Chills—Metformin—polycystic ovary syndrome	0.000937	0.00967	CcSEcCtD
Methotrexate—SLC16A1—adipose tissue—polycystic ovary syndrome	0.000936	0.00562	CbGeAlD
Methotrexate—DHFR—adrenal gland—polycystic ovary syndrome	0.000936	0.00561	CbGeAlD
Methotrexate—Erythema—Metformin—polycystic ovary syndrome	0.000909	0.00938	CcSEcCtD
Methotrexate—Malnutrition—Metformin—polycystic ovary syndrome	0.000909	0.00938	CcSEcCtD
Methotrexate—AOX1—uterus—polycystic ovary syndrome	0.000903	0.00542	CbGeAlD
Methotrexate—PGD—adrenal gland—polycystic ovary syndrome	0.000899	0.0054	CbGeAlD
Methotrexate—MTHFR—endocrine gland—polycystic ovary syndrome	0.000898	0.00539	CbGeAlD
Methotrexate—Dysgeusia—Metformin—polycystic ovary syndrome	0.00089	0.00919	CcSEcCtD
Methotrexate—AOX1—pituitary gland—polycystic ovary syndrome	0.000887	0.00532	CbGeAlD
Methotrexate—SLCO3A1—endocrine gland—polycystic ovary syndrome	0.000884	0.0053	CbGeAlD
Methotrexate—AOX1—adipose tissue—polycystic ovary syndrome	0.000883	0.0053	CbGeAlD
Methotrexate—TYMS—female gonad—polycystic ovary syndrome	0.000881	0.00529	CbGeAlD
Methotrexate—ABCC10—uterus—polycystic ovary syndrome	0.000879	0.00527	CbGeAlD
Methotrexate—TYMS—vagina—polycystic ovary syndrome	0.000876	0.00525	CbGeAlD
Methotrexate—DHFR—female gonad—polycystic ovary syndrome	0.000872	0.00523	CbGeAlD
Methotrexate—DHFR—vagina—polycystic ovary syndrome	0.000867	0.0052	CbGeAlD
Methotrexate—ABCC3—adipose tissue—polycystic ovary syndrome	0.000864	0.00518	CbGeAlD
Methotrexate—ABCC10—pituitary gland—polycystic ovary syndrome	0.000863	0.00518	CbGeAlD
Methotrexate—ABCC10—adipose tissue—polycystic ovary syndrome	0.00086	0.00516	CbGeAlD
Methotrexate—Vision blurred—Metformin—polycystic ovary syndrome	0.000857	0.00884	CcSEcCtD
Methotrexate—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000844	0.00871	CcSEcCtD
Methotrexate—SLC16A1—adrenal gland—polycystic ovary syndrome	0.00084	0.00504	CbGeAlD
Methotrexate—PGD—female gonad—polycystic ovary syndrome	0.000839	0.00503	CbGeAlD
Methotrexate—PGD—vagina—polycystic ovary syndrome	0.000834	0.005	CbGeAlD
Methotrexate—Malaise—Metformin—polycystic ovary syndrome	0.00082	0.00846	CcSEcCtD
Methotrexate—TYMS—endocrine gland—polycystic ovary syndrome	0.000819	0.00492	CbGeAlD
Methotrexate—DHFR—endocrine gland—polycystic ovary syndrome	0.000811	0.00487	CbGeAlD
Methotrexate—AOX1—adrenal gland—polycystic ovary syndrome	0.000792	0.00475	CbGeAlD
Methotrexate—SLC16A1—female gonad—polycystic ovary syndrome	0.000783	0.0047	CbGeAlD
Methotrexate—PGD—endocrine gland—polycystic ovary syndrome	0.00078	0.00468	CbGeAlD
Methotrexate—ABCC3—adrenal gland—polycystic ovary syndrome	0.000775	0.00465	CbGeAlD
Methotrexate—Chest pain—Metformin—polycystic ovary syndrome	0.000774	0.00799	CcSEcCtD
Methotrexate—Myalgia—Metformin—polycystic ovary syndrome	0.000774	0.00799	CcSEcCtD
Methotrexate—ABCC10—adrenal gland—polycystic ovary syndrome	0.000771	0.00463	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000769	0.00793	CcSEcCtD
Methotrexate—Discomfort—Metformin—polycystic ovary syndrome	0.000765	0.00789	CcSEcCtD
Methotrexate—ABCC1—adrenal cortex—polycystic ovary syndrome	0.000756	0.00453	CbGeAlD
Methotrexate—AOX1—female gonad—polycystic ovary syndrome	0.000739	0.00443	CbGeAlD
Methotrexate—Infection—Metformin—polycystic ovary syndrome	0.000737	0.00761	CcSEcCtD
Methotrexate—AOX1—vagina—polycystic ovary syndrome	0.000734	0.00441	CbGeAlD
Methotrexate—ABCC4—uterus—polycystic ovary syndrome	0.000729	0.00437	CbGeAlD
Methotrexate—SLC16A1—endocrine gland—polycystic ovary syndrome	0.000728	0.00437	CbGeAlD
Methotrexate—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000728	0.00751	CcSEcCtD
Methotrexate—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000727	0.0075	CcSEcCtD
Methotrexate—ABCC3—female gonad—polycystic ovary syndrome	0.000723	0.00434	CbGeAlD
Methotrexate—Skin disorder—Metformin—polycystic ovary syndrome	0.000721	0.00744	CcSEcCtD
Methotrexate—ABCC10—female gonad—polycystic ovary syndrome	0.000719	0.00431	CbGeAlD
Methotrexate—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000717	0.0074	CcSEcCtD
Methotrexate—ABCC10—vagina—polycystic ovary syndrome	0.000715	0.00429	CbGeAlD
Methotrexate—ABCC4—adipose tissue—polycystic ovary syndrome	0.000713	0.00428	CbGeAlD
Methotrexate—SLCO1B1—endocrine gland—polycystic ovary syndrome	0.000708	0.00425	CbGeAlD
Methotrexate—Anorexia—Metformin—polycystic ovary syndrome	0.000707	0.0073	CcSEcCtD
Methotrexate—Hypotension—Metformin—polycystic ovary syndrome	0.000693	0.00716	CcSEcCtD
Methotrexate—AOX1—endocrine gland—polycystic ovary syndrome	0.000687	0.00412	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000676	0.00698	CcSEcCtD
Methotrexate—ABCC1—endometrium—polycystic ovary syndrome	0.000675	0.00405	CbGeAlD
Methotrexate—ABCC3—endocrine gland—polycystic ovary syndrome	0.000672	0.00403	CbGeAlD
Methotrexate—ABCC10—endocrine gland—polycystic ovary syndrome	0.000669	0.00401	CbGeAlD
Methotrexate—Paraesthesia—Metformin—polycystic ovary syndrome	0.000666	0.00688	CcSEcCtD
Methotrexate—Dyspnoea—Metformin—polycystic ovary syndrome	0.000662	0.00683	CcSEcCtD
Methotrexate—ALB—adrenal gland—polycystic ovary syndrome	0.000661	0.00396	CbGeAlD
Methotrexate—Somnolence—Metformin—polycystic ovary syndrome	0.00066	0.00681	CcSEcCtD
Methotrexate—Dyspepsia—Metformin—polycystic ovary syndrome	0.000653	0.00674	CcSEcCtD
Methotrexate—Decreased appetite—Metformin—polycystic ovary syndrome	0.000645	0.00666	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000641	0.00661	CcSEcCtD
Methotrexate—Fatigue—Metformin—polycystic ovary syndrome	0.00064	0.0066	CcSEcCtD
Methotrexate—ABCC4—adrenal gland—polycystic ovary syndrome	0.00064	0.00384	CbGeAlD
Methotrexate—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000626	0.00375	CbGeAlD
Methotrexate—ABCC1—uterus—polycystic ovary syndrome	0.000622	0.00373	CbGeAlD
Methotrexate—ABCC2—adrenal gland—polycystic ovary syndrome	0.000619	0.00372	CbGeAlD
Methotrexate—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000612	0.00631	CcSEcCtD
Methotrexate—ABCC1—pituitary gland—polycystic ovary syndrome	0.000611	0.00366	CbGeAlD
Methotrexate—ABCC1—adipose tissue—polycystic ovary syndrome	0.000608	0.00365	CbGeAlD
Methotrexate—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000607	0.00626	CcSEcCtD
Methotrexate—ABCC4—female gonad—polycystic ovary syndrome	0.000597	0.00358	CbGeAlD
Methotrexate—Urticaria—Metformin—polycystic ovary syndrome	0.00059	0.00608	CcSEcCtD
Methotrexate—Abdominal pain—Metformin—polycystic ovary syndrome	0.000587	0.00605	CcSEcCtD
Methotrexate—SLCO1A2—endocrine gland—polycystic ovary syndrome	0.000576	0.00346	CbGeAlD
Methotrexate—ABCG2—endometrium—polycystic ovary syndrome	0.000559	0.00335	CbGeAlD
Methotrexate—ABCC4—endocrine gland—polycystic ovary syndrome	0.000555	0.00333	CbGeAlD
Methotrexate—ABCC1—adrenal gland—polycystic ovary syndrome	0.000546	0.00327	CbGeAlD
Methotrexate—ABCC2—endocrine gland—polycystic ovary syndrome	0.000537	0.00322	CbGeAlD
Methotrexate—Asthenia—Metformin—polycystic ovary syndrome	0.000532	0.00549	CcSEcCtD
Methotrexate—Pruritus—Metformin—polycystic ovary syndrome	0.000525	0.00542	CcSEcCtD
Methotrexate—ABCG2—uterus—polycystic ovary syndrome	0.000515	0.00309	CbGeAlD
Methotrexate—ABCC1—female gonad—polycystic ovary syndrome	0.000509	0.00305	CbGeAlD
Methotrexate—Diarrhoea—Metformin—polycystic ovary syndrome	0.000508	0.00524	CcSEcCtD
Methotrexate—ABCC1—vagina—polycystic ovary syndrome	0.000506	0.00303	CbGeAlD
Methotrexate—ABCG2—pituitary gland—polycystic ovary syndrome	0.000506	0.00303	CbGeAlD
Methotrexate—ABCG2—adipose tissue—polycystic ovary syndrome	0.000503	0.00302	CbGeAlD
Methotrexate—Dizziness—Metformin—polycystic ovary syndrome	0.000491	0.00506	CcSEcCtD
Methotrexate—Vomiting—Metformin—polycystic ovary syndrome	0.000472	0.00487	CcSEcCtD
Methotrexate—Rash—Metformin—polycystic ovary syndrome	0.000468	0.00483	CcSEcCtD
Methotrexate—Dermatitis—Metformin—polycystic ovary syndrome	0.000467	0.00482	CcSEcCtD
Methotrexate—Headache—Metformin—polycystic ovary syndrome	0.000465	0.0048	CcSEcCtD
Methotrexate—ABCG2—adrenal gland—polycystic ovary syndrome	0.000452	0.00271	CbGeAlD
Methotrexate—Nausea—Metformin—polycystic ovary syndrome	0.000441	0.00455	CcSEcCtD
Methotrexate—ABCG2—female gonad—polycystic ovary syndrome	0.000421	0.00253	CbGeAlD
Methotrexate—ABCG2—vagina—polycystic ovary syndrome	0.000419	0.00251	CbGeAlD
Methotrexate—ABCB1—embryo—polycystic ovary syndrome	0.000376	0.00226	CbGeAlD
Methotrexate—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000309	0.00185	CbGeAlD
Methotrexate—ABCB1—endometrium—polycystic ovary syndrome	0.000275	0.00165	CbGeAlD
Methotrexate—ABCB1—uterus—polycystic ovary syndrome	0.000254	0.00152	CbGeAlD
Methotrexate—ABCB1—pituitary gland—polycystic ovary syndrome	0.000249	0.0015	CbGeAlD
Methotrexate—ABCB1—adipose tissue—polycystic ovary syndrome	0.000248	0.00149	CbGeAlD
Methotrexate—ABCB1—adrenal gland—polycystic ovary syndrome	0.000223	0.00134	CbGeAlD
Methotrexate—ABCB1—female gonad—polycystic ovary syndrome	0.000208	0.00125	CbGeAlD
Methotrexate—ABCB1—vagina—polycystic ovary syndrome	0.000206	0.00124	CbGeAlD
Methotrexate—ABCB1—endocrine gland—polycystic ovary syndrome	0.000193	0.00116	CbGeAlD
Methotrexate—ALB—Metabolism—AKR1C2—polycystic ovary syndrome	2.13e-05	0.000104	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TEAD2—polycystic ovary syndrome	2.13e-05	0.000104	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SERPINE1—polycystic ovary syndrome	2.13e-05	0.000104	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP17A1—polycystic ovary syndrome	2.11e-05	0.000103	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CYP19A1—polycystic ovary syndrome	2.11e-05	0.000103	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CYP1A1—polycystic ovary syndrome	2.1e-05	0.000102	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—YAP1—polycystic ovary syndrome	2.08e-05	0.000102	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTHFR—polycystic ovary syndrome	2.08e-05	0.000101	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKR1C1—polycystic ovary syndrome	2.07e-05	0.000101	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GNAS—polycystic ovary syndrome	2.06e-05	0.000101	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CYP1A1—polycystic ovary syndrome	2.05e-05	9.99e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.05e-05	9.99e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLAT—polycystic ovary syndrome	2.04e-05	9.94e-05	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—polycystic ovary syndrome	2.03e-05	9.9e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—LHB—polycystic ovary syndrome	2.03e-05	9.9e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TH—polycystic ovary syndrome	2.02e-05	9.87e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP19A1—polycystic ovary syndrome	2.02e-05	9.84e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.02e-05	9.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SULT2A1—polycystic ovary syndrome	2.01e-05	9.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKR1C3—polycystic ovary syndrome	2.01e-05	9.79e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NAMPT—polycystic ovary syndrome	2e-05	9.76e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.99e-05	9.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HSD3B2—polycystic ovary syndrome	1.98e-05	9.67e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP11A1—polycystic ovary syndrome	1.98e-05	9.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TNRC6B—polycystic ovary syndrome	1.98e-05	9.63e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IRS2—polycystic ovary syndrome	1.97e-05	9.63e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—SLC2A4—polycystic ovary syndrome	1.97e-05	9.6e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—NCOR1—polycystic ovary syndrome	1.97e-05	9.59e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IGF1—polycystic ovary syndrome	1.97e-05	9.59e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT2—polycystic ovary syndrome	1.96e-05	9.58e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.96e-05	9.57e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—polycystic ovary syndrome	1.96e-05	9.57e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—RRM2—polycystic ovary syndrome	1.95e-05	9.49e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IRS1—polycystic ovary syndrome	1.94e-05	9.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	1.94e-05	9.44e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKR1C1—polycystic ovary syndrome	1.92e-05	9.37e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—MTHFR—polycystic ovary syndrome	1.91e-05	9.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SULT2A1—polycystic ovary syndrome	1.91e-05	9.31e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	1.9e-05	9.26e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IRS1—polycystic ovary syndrome	1.89e-05	9.24e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNAS—polycystic ovary syndrome	1.88e-05	9.17e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—YAP1—polycystic ovary syndrome	1.88e-05	9.15e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKR1C3—polycystic ovary syndrome	1.87e-05	9.11e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	1.87e-05	9.11e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	1.87e-05	9.1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	1.87e-05	9.1e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CYP1A1—polycystic ovary syndrome	1.86e-05	9.09e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—INS—polycystic ovary syndrome	1.86e-05	9.06e-05	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	1.86e-05	9.05e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP19A1—polycystic ovary syndrome	1.85e-05	9.03e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—RRM2—polycystic ovary syndrome	1.85e-05	9.02e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP17A1—polycystic ovary syndrome	1.84e-05	8.97e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TH—polycystic ovary syndrome	1.83e-05	8.91e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—INS—polycystic ovary syndrome	1.81e-05	8.85e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NAMPT—polycystic ovary syndrome	1.8e-05	8.79e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNAS—polycystic ovary syndrome	1.8e-05	8.79e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT2—polycystic ovary syndrome	1.8e-05	8.76e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—NCOR1—polycystic ovary syndrome	1.79e-05	8.74e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.79e-05	8.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PNPLA2—polycystic ovary syndrome	1.79e-05	8.71e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—YAP1—polycystic ovary syndrome	1.78e-05	8.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP11A1—polycystic ovary syndrome	1.78e-05	8.68e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—SLC2A4—polycystic ovary syndrome	1.78e-05	8.67e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SULT2A1—polycystic ovary syndrome	1.77e-05	8.62e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.77e-05	8.62e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	1.76e-05	8.61e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT2—polycystic ovary syndrome	1.75e-05	8.55e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—MTHFR—polycystic ovary syndrome	1.74e-05	8.48e-05	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—polycystic ovary syndrome	1.73e-05	8.42e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IRS1—polycystic ovary syndrome	1.72e-05	8.41e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—NCOR1—polycystic ovary syndrome	1.72e-05	8.37e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NAMPT—polycystic ovary syndrome	1.71e-05	8.35e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—RRM2—polycystic ovary syndrome	1.71e-05	8.35e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SERPINE1—polycystic ovary syndrome	1.71e-05	8.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.7e-05	8.3e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CYP1A1—polycystic ovary syndrome	1.7e-05	8.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SRD5A1—polycystic ovary syndrome	1.69e-05	8.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TCF7L2—polycystic ovary syndrome	1.69e-05	8.25e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP11A1—polycystic ovary syndrome	1.69e-05	8.25e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	1.69e-05	8.24e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKR1C3—polycystic ovary syndrome	1.68e-05	8.19e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.68e-05	8.19e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP19A1—polycystic ovary syndrome	1.67e-05	8.15e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—SERPINE1—polycystic ovary syndrome	1.67e-05	8.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	1.66e-05	8.11e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SLC2A4—polycystic ovary syndrome	1.66e-05	8.11e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP17A1—polycystic ovary syndrome	1.65e-05	8.07e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNAS—polycystic ovary syndrome	1.65e-05	8.06e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—INS—polycystic ovary syndrome	1.65e-05	8.05e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—YAP1—polycystic ovary syndrome	1.65e-05	8.05e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP1A1—polycystic ovary syndrome	1.63e-05	7.93e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STAR—polycystic ovary syndrome	1.61e-05	7.87e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	1.61e-05	7.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKR1C3—polycystic ovary syndrome	1.6e-05	7.79e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.6e-05	7.78e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT2—polycystic ovary syndrome	1.6e-05	7.78e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TH—polycystic ovary syndrome	1.59e-05	7.76e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PPARG—polycystic ovary syndrome	1.59e-05	7.74e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PRL—polycystic ovary syndrome	1.59e-05	7.73e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NAMPT—polycystic ovary syndrome	1.59e-05	7.73e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—MTHFR—polycystic ovary syndrome	1.58e-05	7.72e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NCOR1—polycystic ovary syndrome	1.57e-05	7.68e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP17A1—polycystic ovary syndrome	1.57e-05	7.67e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP11A1—polycystic ovary syndrome	1.57e-05	7.64e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNAS—polycystic ovary syndrome	1.56e-05	7.63e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—POMC—polycystic ovary syndrome	1.56e-05	7.63e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	1.56e-05	7.63e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—INS—polycystic ovary syndrome	1.56e-05	7.59e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PPARG—polycystic ovary syndrome	1.55e-05	7.56e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—SLC2A4—polycystic ovary syndrome	1.55e-05	7.55e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	1.55e-05	7.54e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—POMC—polycystic ovary syndrome	1.53e-05	7.45e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—INS—polycystic ovary syndrome	1.52e-05	7.41e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—MTHFR—polycystic ovary syndrome	1.52e-05	7.4e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—SERPINE1—polycystic ovary syndrome	1.52e-05	7.39e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP1A1—polycystic ovary syndrome	1.49e-05	7.28e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNAS—polycystic ovary syndrome	1.49e-05	7.27e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	1.48e-05	7.23e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKR1C3—polycystic ovary syndrome	1.48e-05	7.21e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—polycystic ovary syndrome	1.46e-05	7.13e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP17A1—polycystic ovary syndrome	1.46e-05	7.1e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP19A1—polycystic ovary syndrome	1.45e-05	7.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMMR—polycystic ovary syndrome	1.44e-05	7.02e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TH—polycystic ovary syndrome	1.43e-05	6.98e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NCOR1—polycystic ovary syndrome	1.42e-05	6.93e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STAR—polycystic ovary syndrome	1.41e-05	6.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	1.41e-05	6.9e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PPARG—polycystic ovary syndrome	1.41e-05	6.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC2A4—polycystic ovary syndrome	1.39e-05	6.79e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MTHFR—polycystic ovary syndrome	1.39e-05	6.79e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—POMC—polycystic ovary syndrome	1.39e-05	6.78e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—INS—polycystic ovary syndrome	1.38e-05	6.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSD3B1—polycystic ovary syndrome	1.37e-05	6.7e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TH—polycystic ovary syndrome	1.36e-05	6.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.36e-05	6.62e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.35e-05	6.61e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP1A1—polycystic ovary syndrome	1.35e-05	6.57e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—polycystic ovary syndrome	1.35e-05	6.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NCOR1—polycystic ovary syndrome	1.33e-05	6.48e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC2A4—polycystic ovary syndrome	1.32e-05	6.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP19A1—polycystic ovary syndrome	1.31e-05	6.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRG1—polycystic ovary syndrome	1.3e-05	6.36e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNAS—polycystic ovary syndrome	1.3e-05	6.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.29e-05	6.27e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	1.28e-05	6.26e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—polycystic ovary syndrome	1.28e-05	6.26e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—POMC—polycystic ovary syndrome	1.27e-05	6.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	1.26e-05	6.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	1.26e-05	6.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TH—polycystic ovary syndrome	1.26e-05	6.14e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—INS—polycystic ovary syndrome	1.26e-05	6.14e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTHFR—polycystic ovary syndrome	1.26e-05	6.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LHB—polycystic ovary syndrome	1.25e-05	6.11e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP19A1—polycystic ovary syndrome	1.24e-05	6.07e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.24e-05	6.03e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—polycystic ovary syndrome	1.23e-05	6e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—polycystic ovary syndrome	1.23e-05	6e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC2A4—polycystic ovary syndrome	1.23e-05	5.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSD3B2—polycystic ovary syndrome	1.22e-05	5.97e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—POMC—polycystic ovary syndrome	1.21e-05	5.92e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—INS—polycystic ovary syndrome	1.21e-05	5.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	1.2e-05	5.87e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.19e-05	5.79e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1C1—polycystic ovary syndrome	1.19e-05	5.78e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTHFR—polycystic ovary syndrome	1.17e-05	5.73e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.17e-05	5.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNAS—polycystic ovary syndrome	1.17e-05	5.7e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP19A1—polycystic ovary syndrome	1.15e-05	5.62e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—polycystic ovary syndrome	1.13e-05	5.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS2—polycystic ovary syndrome	1.12e-05	5.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NCOR1—polycystic ovary syndrome	1.11e-05	5.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—POMC—polycystic ovary syndrome	1.11e-05	5.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNAS—polycystic ovary syndrome	1.11e-05	5.42e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—INS—polycystic ovary syndrome	1.11e-05	5.4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.1e-05	5.35e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.09e-05	5.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	1.09e-05	5.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.07e-05	5.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NCOR1—polycystic ovary syndrome	1.06e-05	5.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—RRM2—polycystic ovary syndrome	1.06e-05	5.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1A1—polycystic ovary syndrome	1.06e-05	5.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.04e-05	5.06e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	1.03e-05	5.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—YAP1—polycystic ovary syndrome	1.02e-05	4.97e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—polycystic ovary syndrome	1.02e-05	4.96e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IGF1—polycystic ovary syndrome	1.01e-05	4.94e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT2—polycystic ovary syndrome	1.01e-05	4.94e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—POMC—polycystic ovary syndrome	1e-05	4.9e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1A1—polycystic ovary syndrome	1e-05	4.89e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—INS—polycystic ovary syndrome	9.98e-06	4.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—polycystic ovary syndrome	9.84e-06	4.8e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	9.79e-06	4.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NAMPT—polycystic ovary syndrome	9.78e-06	4.77e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS1—polycystic ovary syndrome	9.75e-06	4.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	9.73e-06	4.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	9.66e-06	4.71e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	9.62e-06	4.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	9.59e-06	4.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	9.56e-06	4.66e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—polycystic ovary syndrome	9.35e-06	4.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—INS—polycystic ovary syndrome	9.34e-06	4.56e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	9.28e-06	4.53e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	9.25e-06	4.51e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	9.12e-06	4.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT2—polycystic ovary syndrome	9.03e-06	4.4e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	8.98e-06	4.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	8.92e-06	4.35e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—polycystic ovary syndrome	8.86e-06	4.32e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—POMC—polycystic ovary syndrome	8.74e-06	4.26e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—INS—polycystic ovary syndrome	8.69e-06	4.24e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	8.66e-06	4.22e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—polycystic ovary syndrome	8.58e-06	4.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	8.57e-06	4.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	8.46e-06	4.13e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—polycystic ovary syndrome	8.12e-06	3.96e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	7.99e-06	3.9e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—polycystic ovary syndrome	7.98e-06	3.89e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—polycystic ovary syndrome	7.93e-06	3.87e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	7.87e-06	3.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—POMC—polycystic ovary syndrome	7.87e-06	3.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—INS—polycystic ovary syndrome	7.82e-06	3.82e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TH—polycystic ovary syndrome	7.77e-06	3.79e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—polycystic ovary syndrome	7.58e-06	3.7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	7.56e-06	3.69e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—POMC—polycystic ovary syndrome	7.48e-06	3.65e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—INS—polycystic ovary syndrome	7.43e-06	3.63e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—polycystic ovary syndrome	7.21e-06	3.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	7.11e-06	3.47e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	7.02e-06	3.42e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—POMC—polycystic ovary syndrome	6.92e-06	3.38e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—INS—polycystic ovary syndrome	6.88e-06	3.36e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TH—polycystic ovary syndrome	6.81e-06	3.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	6.62e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	6.62e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNAS—polycystic ovary syndrome	6.34e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	6.23e-06	3.04e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOR1—polycystic ovary syndrome	6.04e-06	2.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	5.73e-06	2.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	5.56e-06	2.71e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—polycystic ovary syndrome	5.34e-06	2.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	5.3e-06	2.58e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	5.02e-06	2.45e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	4.68e-06	2.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—polycystic ovary syndrome	4.33e-06	2.11e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POMC—polycystic ovary syndrome	4.27e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—INS—polycystic ovary syndrome	4.25e-06	2.07e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—polycystic ovary syndrome	4.08e-06	1.99e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	3.79e-06	1.85e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POMC—polycystic ovary syndrome	3.74e-06	1.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—INS—polycystic ovary syndrome	3.72e-06	1.82e-05	CbGpPWpGaD
